PERCEPTIVE INFORMATICS COMPLETES OVER 500 SYSTEM INTEGRATIONS AS THE BIOPHARMA INDUSTRY CONTINUES TO ADOPT SEAMLESS ECLINICAL SOLUTIONS
Boston, MA, December 15, 2011—As the biopharmaceutical industry continues to migrate toward the use of more seamless eClinical solutions to accelerate clinical development, Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), has reached a milestone of completing more than 500 integration projects to connect disparate applications across clinical technology systems provided by multiple vendors. Perceptive’s integration solutions are delivered by its dedicated eClinical Technology Services experts who have an in-depth understanding of advanced technologies, clinical development processes and validated system integrations.
“With standalone systems, the opportunity to maximally leverage technology has been extremely limited. The biopharmaceutical industry is moving toward using a more convergent solution, built on top of a common platform, as we’ve seen in the ERP software segment. Over the last few years and literally hundreds of integrations, we have begun to identify patterns and platform solutions that enable our customers to take advantage of technology in a more efficient and cost effective manner,” said Nick Richards, Vice President, Product Management, Perceptive Informatics.
According to Mr. Richards, “At Perceptive, while we have been helping companies to integrate diverse applications, in parallel we have been investing in actively pursuing our vision to create a tightly woven ecosystem of solutions underpinned by a robust eClinical platform—to allow our customers to achieve new levels of collaboration, insights, and efficiencies. We continue to drive innovation to enable a shift in the way technologies are used in the biopharmaceutical industry. This has never been more true for us here at Perceptive as we prepare the launch of exciting new solutions in 2012.”
Focused on the development of product convergence in eClinical solutions, Perceptive has achieved a new level of functional interoperability among its applications to facilitate greater efficiency of clinical trials. Powered by foundational technologies that enable applications within its own eClinical Suite, Perceptive's eClinical platform incorporates reporting, integration, and identity management solutions, among others. This Clinical Technology Integration Platform (CTIP) underpins Perceptive’s integration solutions and services. Built on proven middleware, this environment is designed to support seamless, real-time two-way exchange of data across different systems.
For more information about Perceptive Informatics’ integration services capabilities visit: http://www.perceptive.com/solutions/integration.
# # #
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 67 locations throughout 52 countries around the world, and has approximately 10,850 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.